Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionMan Group plc
Latest Disclosed Ownership232,369 shares
Latest Disclosed Value $ 76,883,931
Man Group plc reports 61.13% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Man Group plc filed a 13F-HR form disclosing ownership of 232,369 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $66,387,823 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 144,210 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 61.13% during the quarter. The current value of the position is $58,510,514 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 232,369 88,159 61.13 76,884 34.07 0.1395
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 144,210 72,537 101.21 57,345 75.46 0.0975
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 71,673 63,564 783.87 32,683 1,136.08 0.0568
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 8,109 1,038 14.68 2,644 38.50 0.0050
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,071 -9,311 -56.84 1,909 -50.47 0.0048
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,382 -93,421 -85.08 3,855 -87.24 0.0101
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 109,803 -8,107 -6.88 30,199 5.40 0.0786
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 117,910 -92,325 -43.92 28,652 -8.81 0.0724
2024-05-15 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 210,235 167,345 390.17 31,420 282.74 0.0792
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 42,890 8,210 128.41 0.0229
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,594 -62.66 0.0111
2023-08-14 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 50,679 9,626 -63.37 0.0297
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 26,277 5,912.81 0.0935
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,841 523 39.68 438 65.53 0.0016
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,318 264 -97.08 0.0012
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 9,034 3,933.04 0.0383
2022-05-16 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,374 1,374 224 0.0008
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -3,443 -100.00 0 -100.00
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,443 3,443 650 0.0023
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -19,992 -100.00 0 -100.00
2021-02-16 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,992 -1,921 -8.77 2,598 -18.58 0.0114
2020-11-16 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 21,913 -36,971 -62.79 3,191 -63.41 0.0126
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 58,884 56,184 2,080.89 8,721 2,866.33 0.0440
2020-05-15 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,700 -515 -16.02 294 -20.54 0.0019
2020-02-18 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,215 -8,255 -71.97 370 -59.91 0.0012
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 11,470 -25,482 -68.96 923 -65.57 0.0034
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 36,952 16,890 84.19 2,681 42.99 0.0097
2019-05-15 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,062 -2,017 -9.14 1,875 16.46 0.0071
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 22,079 -3,281 -12.94 1,610 -27.48 0.0072
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 25,360 -9,810 -27.89 2,220 -35.91 0.0081
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 35,170 32,770 1,365.42 3,464 1,111.19 0.0143
2018-05-15 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,400 2,400 286 0.0013
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.